Andras Heczey
- Oncology top 2%
- CAR-T cell therapy research 20
- Immunology top 5%
- Immune Cell Function and Interaction 11
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis 9
- Neurology top 5%
- Neuroblastoma Research and Treatments 17
- Genetics top 5%
- Virus-based gene therapy research 6
- Blood disorders and treatments 3
-
- Childhood Cancer Survivors' Quality of Life 4
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 4
- Co-authors
- Gianpietro DottiLeonid S. MetelitsaAmy N. CourtneyLinjie GuoDaofeng LiuEkaterina MarinovaHao LiuBarbara Savoldo
- Cited by
- OncologyImmunologyHepatology
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Investigation (2 papers)Nature Medicine (2 papers)
- Partner nations
- United StatesIrelandThailand
In The Last Decade
Andras Heczey
44 papers receiving 2.0k citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Oncology 1.5k
- Immunology 898
- Hepatology 194
- Neurology 267
- Genetics 378
Countries citing papers authored by Andras Heczey
This map shows the geographic impact of Andras Heczey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andras Heczey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andras Heczey more than expected).
Fields of papers citing papers by Andras Heczey
This network shows the impact of papers produced by Andras Heczey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andras Heczey. The network helps show where Andras Heczey may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Andras Heczey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastomabreakdown → | 2025 | 14 |
| 2 | 2025 | 0 | |
| 3 | 2024 | 0 | |
| 4 | 2023 | 19 | |
| 5 | 2023 | 5 | |
| 6 | 2021 | 5 | |
| 7 | 2020 | 193 | |
| 8 | 2020 | 3 | |
| 9 | 2020 | 8 | |
| 10 | 2020 | 201 | |
| 11 | 2019 | 133 | |
| 12 | 2018 | 1 | |
| 13 | 2017 | 30 | |
| 14 | CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastomabreakdown → | 2017 | 391 |
| 15 | 2017 | 30 | |
| 16 | 2017 | 23 | |
| 17 | 2017 | 0 | |
| 18 | 2016 | 142 | |
| 19 | 2015 | 3 | |
| 20 | 2014 | 41 |
About Andras Heczey
Andras Heczey is a scholar working on Hepatology, Neurology and Oncology, having authored 49 papers that have together received 2.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (20 papers), Neuroblastoma Research and Treatments (17 papers), Immune Cell Function and Interaction (11 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers), Virus-based gene therapy research (6 papers), Childhood Cancer Survivors' Quality of Life (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Blood disorders and treatments (3 papers). The work is most often cited by research in Oncology (1.5k citations), Immunology (898 citations) and Hepatology (194 citations). Andras Heczey has collaborated with scholars based in United States, Ireland and Thailand. Frequent co-authors include Gianpietro Dotti, Leonid S. Metelitsa, Amy N. Courtney, Linjie Guo, Daofeng Liu, Ekaterina Marinova, Hao Liu, Barbara Savoldo, Chrystal U. Louis and Xiuhua Gao. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.